- Takakura, Kazuki;
- Torisu, Yuichi;
- Kinoshita, Yuji;
- Tomita, Yoichi;
- Nakano, Masanori;
- Oikawa, Tsunekazu;
- Tsukinaga, Shintaro;
- Sumiyama, Kazuki;
- Eibl, Guido;
- Saruta, Masayuki
Pancreatic intraductal papillary mucinous neoplasm was originally regarded as a benign mucinous cystic tumor but certainly has a marked malignant potential. With the array of high-resolution imaging modalities that are now available, more frequent incidental asymptomatic intraductal papillary mucinous neoplasm patients can be diagnosed. Until now, our clinicians have been managing intraductal papillary mucinous neoplasm patients by referring to the international consensus guidelines which have been revised twice or American Gastroenterological Association guidelines. The aim of this review is to reassess the current guidelines for the management of malignancy in intraductal papillary mucinous neoplasm. Furthermore, we specifically discuss the problems to be solved for establishing more refined guideline for the early detection, risk stratification and better management of pancreatic cancer in intraductal papillary mucinous neoplasm patients.